FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753406548> ?p ?o ?g. }

• W2753406548 abstract "Background PSUMMIT 1 and PSUMMIT 2 were Phase 3 trials of ustekinumab (UST) in adults with PsA. Objectives Evaluate the efficacy of UST by prior treatment exposure and disease duration in PsA patients (pts) in PSUMMIT 1 and 2. Methods Pts had active PsA (≥5 swollen, ≥5 tender joints, CRP ≥3.0mg/dL,) for ≥6 mos despite treatment with DMARDs and/or NSAIDs (PSUMMIT 1) or DMARDs, NSAIDs, and/or anti-tumor necrosis factor (TNF) agents (PSUMMIT 2). In both studies, pts were randomized to SC injections of placebo (PBO) or UST 45mg or 90mg at wks 0, 4 and every 12 wks. PBO pts crossed over to UST 45mg at wk 24. At wk 16, early escape (PBO –> UST45mg; UST45mg –> UST90mg; UST90mg –> UST90mg) was possible. Stable doses of MTX were allowed. Pooled data from both PSUMMIT 1 and 2 were analyzed. Efficacy assessments included ACR response, DAS28-CRP response, DAS28-CRP remission (score Results In the pooled data, 747 pts were anti-TNF-naive (53.8% were male; mean age=47 years); 179 pts were MTX- and anti-TNF-naive (63.7% were male; mean age =47 years); 146 pts were all DMARD- and anti-TNF-naive (61.0% male; mean age=46 years). In all three prior treatment populations significantly greater proportions of pts in the combined UST group vs PBO achieved an ACR20, ACR50, or ACR70 at wk 24. (Table). Similarly, greater proportions of pts in the combined UST group had DAS28-CRP response or remission vs PBO across all three prior treatment populations. In anti-TNF-naive pts, improvements in enthesitis and dactylitis were significantly greater in the combined UST group vs PBO, and mean change in total vdH-S score was significantly greater for pts in the PBO group than the combined UST group; comparable trends were observed for the MTX- and anti-TNF-naive pts and all DMARD- and anti-TNF-naive pts, but did not reach statistical significance due to the smaller sample sizes in both subgroups. Among anti-TNF-naive pts treated with UST, ACR20/50/70 response rates were similar across different PsA disease duration groups at early time-points (either wk4 or wk16). Conclusions UST-treated patients had greater improvements in signs and symptoms of PsA regardless of prior treatment exposure and disease duration. Disclosure of Interest I. McInnes Consultant for: Janssen Research & Development, LLC, S. Chakravarty Employee of: Janssen Scientific Affairs, LLC, G. Morgan Employee of: Janssen Scientific Affairs, LLC, I. Apaolaza Employee of: Janssen Biologics, BV, S. Kafka Employee of: Janssen Scientific Affairs, LLC, E. Hsia Employee of: Janssen Research & Development, LLC, M. Song Employee of: Janssen Research & Development, LLC, Y. You Employee of: Janssen Research & Development, LLC, A. Kavanaugh Consultant for: Janssen Research & Development, LLC" @default.
• W2753406548 created "2017-09-15" @default.
• W2753406548 creator A5019115968 @default.
• W2753406548 creator A5030429544 @default.
• W2753406548 creator A5035197780 @default.
• W2753406548 creator A5036723767 @default.
• W2753406548 creator A5053163623 @default.
• W2753406548 creator A5058110978 @default.
• W2753406548 creator A5071482630 @default.
• W2753406548 creator A5080643759 @default.
• W2753406548 creator A5085567328 @default.
• W2753406548 date "2017-06-01" @default.
• W2753406548 modified "2023-09-23" @default.
• W2753406548 title "SAT0453 Efficacy of ustekinumab in psoriatic arthritis patients by prior treatment exposure and disease duration: data from psummit 1 and psummit 2" @default.
• W2753406548 doi "https://doi.org/10.1136/annrheumdis-2017-eular.4538" @default.
• W2753406548 hasPublicationYear "2017" @default.
• W2753406548 type Work @default.
• W2753406548 sameAs 2753406548 @default.
• W2753406548 citedByCount "0" @default.
• W2753406548 crossrefType "proceedings-article" @default.
• W2753406548 hasAuthorship W2753406548A5019115968 @default.
• W2753406548 hasAuthorship W2753406548A5030429544 @default.
• W2753406548 hasAuthorship W2753406548A5035197780 @default.
• W2753406548 hasAuthorship W2753406548A5036723767 @default.
• W2753406548 hasAuthorship W2753406548A5053163623 @default.
• W2753406548 hasAuthorship W2753406548A5058110978 @default.
• W2753406548 hasAuthorship W2753406548A5071482630 @default.
• W2753406548 hasAuthorship W2753406548A5080643759 @default.
• W2753406548 hasAuthorship W2753406548A5085567328 @default.
• W2753406548 hasBestOaLocation W27534065481 @default.
• W2753406548 hasConcept C126322002 @default.
• W2753406548 hasConcept C142724271 @default.
• W2753406548 hasConcept C17991360 @default.
• W2753406548 hasConcept C204787440 @default.
• W2753406548 hasConcept C27081682 @default.
• W2753406548 hasConcept C2776260265 @default.
• W2753406548 hasConcept C2777077863 @default.
• W2753406548 hasConcept C2778975655 @default.
• W2753406548 hasConcept C2780132546 @default.
• W2753406548 hasConcept C71924100 @default.
• W2753406548 hasConcept C90924648 @default.
• W2753406548 hasConceptScore W2753406548C126322002 @default.
• W2753406548 hasConceptScore W2753406548C142724271 @default.
• W2753406548 hasConceptScore W2753406548C17991360 @default.
• W2753406548 hasConceptScore W2753406548C204787440 @default.
• W2753406548 hasConceptScore W2753406548C27081682 @default.
• W2753406548 hasConceptScore W2753406548C2776260265 @default.
• W2753406548 hasConceptScore W2753406548C2777077863 @default.
• W2753406548 hasConceptScore W2753406548C2778975655 @default.
• W2753406548 hasConceptScore W2753406548C2780132546 @default.
• W2753406548 hasConceptScore W2753406548C71924100 @default.
• W2753406548 hasConceptScore W2753406548C90924648 @default.
• W2753406548 hasLocation W27534065481 @default.
• W2753406548 hasOpenAccess W2753406548 @default.
• W2753406548 hasPrimaryLocation W27534065481 @default.
• W2753406548 hasRelatedWork W1974936542 @default.
• W2753406548 hasRelatedWork W1995615655 @default.
• W2753406548 hasRelatedWork W2072598730 @default.
• W2753406548 hasRelatedWork W2316630629 @default.
• W2753406548 hasRelatedWork W2321621626 @default.
• W2753406548 hasRelatedWork W2324609475 @default.
• W2753406548 hasRelatedWork W2329145945 @default.
• W2753406548 hasRelatedWork W2331173355 @default.
• W2753406548 hasRelatedWork W2331891368 @default.
• W2753406548 hasRelatedWork W2332263397 @default.
• W2753406548 hasRelatedWork W2332319934 @default.
• W2753406548 hasRelatedWork W2334742820 @default.
• W2753406548 hasRelatedWork W2338123917 @default.
• W2753406548 hasRelatedWork W2557106421 @default.
• W2753406548 hasRelatedWork W2754366759 @default.
• W2753406548 hasRelatedWork W2754453631 @default.
• W2753406548 hasRelatedWork W2901493692 @default.
• W2753406548 hasRelatedWork W2947570513 @default.
• W2753406548 hasRelatedWork W2951386253 @default.
• W2753406548 hasRelatedWork W3130397195 @default.
• W2753406548 isParatext "false" @default.
• W2753406548 isRetracted "false" @default.
• W2753406548 magId "2753406548" @default.
• W2753406548 workType "article" @default.